martes, 10 de diciembre de 2019

H.R. 3 is the wrong path to lower drug costs - STAT

H.R. 3 is the wrong path to lower drug costs - STAT

Daily Recap

Opinion: H.R. 3 is the wrong path to lower drug costs

By MIKE GUERRA


ZACH GIBSON/GETTY IMAGES
A new report shows that lowering drug costs in Medicare Part D by adopting international reference pricing would have a devastating effect on innovation.

No hay comentarios: